Cargando…
Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome
BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830114/ https://www.ncbi.nlm.nih.gov/pubmed/35144622 http://dx.doi.org/10.1186/s12931-022-01944-8 |
_version_ | 1784648209599037440 |
---|---|
author | Paul, Oindrila Tao, Jian Qin West, Eric Litzky, Leslie Feldman, Michael Montone, Kathleen Rajapakse, Chamith Bermudez, Christian Chatterjee, Shampa |
author_facet | Paul, Oindrila Tao, Jian Qin West, Eric Litzky, Leslie Feldman, Michael Montone, Kathleen Rajapakse, Chamith Bermudez, Christian Chatterjee, Shampa |
author_sort | Paul, Oindrila |
collection | PubMed |
description | BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensive inflammation and injury, but the extent to which these are a COVID-19 specific, or are an ARDS and/or mechanical ventilation (MV) related phenomenon is not clear. Furthermore, while lung hyperinflammation with ARDS (COVID-19 or from other causes) has been well studied, there is scarce documentation of vascular inflammation in COVID-19 lungs. METHODS: Lung sections from 8 COVID-19 affected and 11 non-COVID-19 subjects, of which 8 were acute respiratory disease syndrome (ARDS) affected (non-COVID-19 ARDS) and 3 were from subjects with non-respiratory diseases (non-COVID-19 non-ARDS) were H&E stained to ascertain histopathological features. Inflammation along the vessel wall was also monitored by expression of NLRP3 and caspase 1. RESULTS: In lungs from COVID-19 affected subjects, vascular changes in the form of microthrombi in small vessels, arterial thrombosis, and organization were extensive as compared to lungs from non-COVID-19 (i.e., non-COVID-19 ARDS and non-COVID-19 non-ARDS) affected subjects. The expression of NLRP3 pathway components was higher in lungs from COVID-19 ARDS subjects as compared to non-COVID-19 non-ARDS cases. No differences were observed between COVID-19 ARDS and non-COVID-19 ARDS lungs. CONCLUSION: Vascular changes as well as NLRP3 inflammasome pathway activation were not different between COVID-19 and non-COVID-19 ARDS suggesting that these responses are not a COVID-19 specific phenomenon and are possibly more related to respiratory distress and associated strategies (such as MV) for treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01944-8. |
format | Online Article Text |
id | pubmed-8830114 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88301142022-02-11 Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome Paul, Oindrila Tao, Jian Qin West, Eric Litzky, Leslie Feldman, Michael Montone, Kathleen Rajapakse, Chamith Bermudez, Christian Chatterjee, Shampa Respir Res Research BACKGROUND: Pulmonary hyperinflammation is a key event with SARS-CoV-2 infection. Acute respiratory distress syndrome (ARDS) that often accompanies COVID-19 appears to have worse outcomes than ARDS from other causes. To date, numerous lung histological studies in cases of COVID-19 have shown extensive inflammation and injury, but the extent to which these are a COVID-19 specific, or are an ARDS and/or mechanical ventilation (MV) related phenomenon is not clear. Furthermore, while lung hyperinflammation with ARDS (COVID-19 or from other causes) has been well studied, there is scarce documentation of vascular inflammation in COVID-19 lungs. METHODS: Lung sections from 8 COVID-19 affected and 11 non-COVID-19 subjects, of which 8 were acute respiratory disease syndrome (ARDS) affected (non-COVID-19 ARDS) and 3 were from subjects with non-respiratory diseases (non-COVID-19 non-ARDS) were H&E stained to ascertain histopathological features. Inflammation along the vessel wall was also monitored by expression of NLRP3 and caspase 1. RESULTS: In lungs from COVID-19 affected subjects, vascular changes in the form of microthrombi in small vessels, arterial thrombosis, and organization were extensive as compared to lungs from non-COVID-19 (i.e., non-COVID-19 ARDS and non-COVID-19 non-ARDS) affected subjects. The expression of NLRP3 pathway components was higher in lungs from COVID-19 ARDS subjects as compared to non-COVID-19 non-ARDS cases. No differences were observed between COVID-19 ARDS and non-COVID-19 ARDS lungs. CONCLUSION: Vascular changes as well as NLRP3 inflammasome pathway activation were not different between COVID-19 and non-COVID-19 ARDS suggesting that these responses are not a COVID-19 specific phenomenon and are possibly more related to respiratory distress and associated strategies (such as MV) for treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-01944-8. BioMed Central 2022-02-10 2022 /pmc/articles/PMC8830114/ /pubmed/35144622 http://dx.doi.org/10.1186/s12931-022-01944-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Paul, Oindrila Tao, Jian Qin West, Eric Litzky, Leslie Feldman, Michael Montone, Kathleen Rajapakse, Chamith Bermudez, Christian Chatterjee, Shampa Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title | Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title_full | Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title_fullStr | Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title_full_unstemmed | Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title_short | Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome |
title_sort | pulmonary vascular inflammation with fatal coronavirus disease 2019 (covid-19): possible role for the nlrp3 inflammasome |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830114/ https://www.ncbi.nlm.nih.gov/pubmed/35144622 http://dx.doi.org/10.1186/s12931-022-01944-8 |
work_keys_str_mv | AT pauloindrila pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT taojianqin pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT westeric pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT litzkyleslie pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT feldmanmichael pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT montonekathleen pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT rajapaksechamith pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT bermudezchristian pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome AT chatterjeeshampa pulmonaryvascularinflammationwithfatalcoronavirusdisease2019covid19possibleroleforthenlrp3inflammasome |